Hypertension secondary to endocrine disorders
ICD-10 I15.2 is a billable code used to indicate a diagnosis of hypertension secondary to endocrine disorders.
Hypertension secondary to endocrine disorders, coded as I15.2, refers to elevated blood pressure resulting from underlying endocrine conditions such as hyperaldosteronism, Cushing's syndrome, pheochromocytoma, and thyroid disorders. Clinically, patients may present with symptoms of hypertension, headaches, palpitations, and signs of the specific endocrine disorder. The anatomy involved primarily includes the adrenal glands, thyroid gland, and the hypothalamic-pituitary axis, which regulate hormone production affecting blood pressure. Disease progression can lead to complications such as cardiovascular disease, renal impairment, and stroke if not managed effectively. Diagnostic considerations include a thorough patient history, physical examination, and laboratory tests to identify the underlying endocrine disorder. Imaging studies may also be warranted to assess for tumors or structural abnormalities contributing to hypertension. Accurate diagnosis is crucial for effective treatment and management of both hypertension and the underlying endocrine disorder.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
I15.2 covers hypertension secondary to conditions such as primary hyperaldosteronism, Cushing's syndrome, pheochromocytoma, and hyperthyroidism. Each condition has specific diagnostic criteria that must be met for accurate coding.
I15.2 should be used when hypertension is directly attributable to an endocrine disorder, as opposed to I15.0 or I15.1, which pertain to renal or other specified causes. Clear documentation linking the hypertension to the endocrine disorder is essential.
Documentation should include a confirmed diagnosis of the underlying endocrine disorder, relevant laboratory results, imaging studies if applicable, and a clear note on how the endocrine disorder contributes to the patient's hypertension.
